AXIM Biotech Files IP Application on Proprietary Method to Extract High-Purity THC

Published on

Proprietary method in collaboration with Syncom B.V. will achieve a THC purity level greater than 95%.

AXIM Biotechnologies, Inc. (AXIM® Biotech), a world leader in cannabinoid research and development, announced today that it filed an IP application with the World Intellectual Property Organization (WIPO) on a proprietary method to extract THC-A (tetrahydrocannabinol acid) from cannabis plants and to achieve THC (tetrahydrocannabinol) with higher purity than conventional methods.

The IP was generated in collaboration with Syncom B.V., a Netherlands-based leading company in custom synthesis solutions for pharmaceutical and biotech industry.

“We are pleased to announce the IP application of our own THC extraction method. There are many THC-based products on the market but none are pure grade. Our application, developed in conjunction with Syncom, is a game changer as the extraction method produces THC in the purest form. In addition, this new method will allow us to have the highest THC yields with no heavy metals, solvents or other unwanted residues,” said George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM® Biotech. “This new extraction application attests to the high competence of the AXIM research and development team, and will go a long way in supporting our mission in finding cannabinoid-derived solutions for health conditions with no known cure.”

Dr. Ton Vries, CEO of Syncom, adds: “Syncom is glad to have made a relevant contribution to the novel extraction of THC. We will continue in collaborating with Axim and proceed with the development of state of the art active pharmaceutical Ingredients derived from the Cannabis plant”.

Read more HERE.


Do you have a question?

Do you want to stay updated on Syncom’s activities? Follow us on LinkedIn or contact us here.